Alnylam Submits Applications In U.S, EU To Support Label Expansion For Oxlumo For PH1 Treatment
14/12 13:47
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) said that it has submitted a supplemental New Drug Application or sNDA to the U.S. Food and Drug Administration and Type II Filing Variation to the European Medicines Agency for lumasiran, an investigational RNAi therapeutic targeti...